NASDAQ:VCYT - Veracyte Stock Price, Forecast & News

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings results on Tuesday, October, 22nd. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.05. The biotechnology company had revenue of $30.97 million for the quarter, compared to the consensus estimate of $30.41 million. Veracyte had a negative net margin of 7.08% and a negative return on equity of 5.33%. View Veracyte's Earnings History.

Veracyte is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Veracyte.

2 brokers have issued twelve-month target prices for Veracyte's stock. Their forecasts range from $34.00 to $35.00. On average, they anticipate Veracyte's stock price to reach $34.50 in the next twelve months. This suggests a possible upside of 25.5% from the stock's current price. View Analyst Price Targets for Veracyte.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.

Press coverage about VCYT stock has trended very negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Veracyte earned a coverage optimism score of -3.7 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days. View News Stories for Veracyte.

Veracyte saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 2,610,000 shares, a decline of 5.4% from the November 28th total of 2,760,000 shares. Based on an average daily volume of 591,300 shares, the short-interest ratio is currently 4.4 days. Currently, 5.7% of the company's stock are short sold. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), AbbVie (ABBV), InVitae (NVTA), Exelixis (EXEL), NeoGenomics (NEO), Netflix (NFLX) and Chipotle Mexican Grill (CMG).

Veracyte's stock is owned by a number of of retail and institutional investors. Top institutional investors include KAMES CAPITAL plc (0.42%), Falcon Point Capital LLC (0.10%), Assenagon Asset Management S.A. (0.07%), Strs Ohio (0.06%), Calamos Advisors LLC (0.05%) and Exchange Traded Concepts LLC (0.01%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Institutional Ownership Trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Falcon Point Capital LLC and Strs Ohio. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Insider Buying and Selling for Veracyte.

VCYT stock was bought by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Assenagon Asset Management S.A., Exchange Traded Concepts LLC and FTB Advisors Inc.. View Insider Buying and Selling for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $27.49.

Veracyte has a market capitalization of $1.34 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.

The official website for Veracyte is http://www.veracyte.com/.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]